



ASX Announcement/Press Release | 19 May 2025
AdAlta Limited (ASX:1AD)

Investor webinar invitation: Entitlement Offer and strategic opportunities

AdAlta Limited (ASX:1AD) will host an investor webinar on Thursday 22 May 2025.

The webinar will be presented by AdAlta's Chief Executive Officer & Managing Director, Dr Tim Oldham, and will be followed by a short Q&A session.

In his webinar presentation, Dr Oldham will discuss AdAlta's strategic opportunities and current Entitlement Offer, including:

- AdAlta's "East to West" cellular immunotherapy strategy as a key driver of future pipeline growth
- The value in existing assets: AD-214 for fibrotic disease and WD-34 for malaria
- Other strategic options

AdAlta Investor Webinar Registration Details:

DATE: Thursday 22 May 2025

TIME: 1:00 pm AEST

FORMAT: Zoom

Please register in advance using the following link:

https://us02web.zoom.us/webinar/register/WN_o2rqT_k7RWqMoyTy3acLbQ

After registering, you will receive a confirmation email containing information about joining the webinar.

Reference Documents:

- ASX announcement: Renounceable rights issue to raise up to \$1.3 million
<https://investorhub.adalta.com.au/announcements/6937327>
- ASX announcement: Prospectus <https://investorhub.adalta.com.au/announcements/6941925>
- ASX announcement: Investor presentation
<https://investorhub.adalta.com.au/announcements/6944560>

To further engage with this announcement or the webinar, please visit AdAlta's InvestorHub here:
<https://investorhub.adalta.com.au/link/mPqY8P>

This ASX announcement has been authorised by the CEO and Managing Director of AdAlta Limited.

For further information, please contact:

AdAlta Limited (ASX:1AD)

Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au

Media & Investor Enquiries

The Capital Network
Julia Maguire
P: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About AdAlta

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its 'East to West' strategy, the Company is integrating Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting 'Eastern' innovation in cellular immunotherapies with 'Western' regulated markets and patients.

AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.

AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US\$20.3 billion by 2028.

AdAlta's first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering.

To learn more, please visit: www.adalta.com.au

For more information



Join our [InvestorHub](#)

Follow us on [LinkedIn](#)

Follow us on [X \(formerly Twitter\)](#)